Kite Pharma, Inc.;The United States of America, as represented by The Secretary, Department of Health and Human Services;The United States of America, as represented by The Secretary, Department of He
发明人:
BOT, Adrian,WIEZOREK, Jeffrey S.,GO, William,JAIN, Rajul,KOCHENDERFER, James N.,ROSENBERG, Steven A.,JAIN, Rajul,R‧賈因,KOCHENDERFER, James N.,J‧N‧科亨德費爾,ROSENBERG, Steven A.,S‧A‧羅森堡
申请号：
HK18105539.7
公开号：
HK1246150A
申请日:
2018.04.27
申请国别(地区):
HK
年份:
2018
代理人:
摘要：
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
